Harper L - Search Results

1

Avoidance of Harm From Treatment for ANCA-Associated Vasculitis.

King C, Harper L. King C, et al. Among authors: harper l. Curr Treatm Opt Rheumatol. 2017;3(4):230-243. doi: 10.1007/s40674-017-0082-y. Epub 2017 Nov 13. Curr Treatm Opt Rheumatol. 2017. PMID: 29201630 Free PMC article. Review.

2

Malignancy is increased in ANCA-associated vasculitis.

Pankhurst T, Savage CO, Gordon C, Harper L. Pankhurst T, et al. Among authors: harper l. Rheumatology (Oxford). 2004 Dec;43(12):1532-5. doi: 10.1093/rheumatology/keh374. Epub 2004 Aug 17. Rheumatology (Oxford). 2004. PMID: 15316126

3

ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients.

Harper L, Savage CO. Harper L, et al. Rheumatology (Oxford). 2005 Apr;44(4):495-501. doi: 10.1093/rheumatology/keh522. Epub 2004 Dec 21. Rheumatology (Oxford). 2005. PMID: 15613403

4

Recent advances to achieve remission induction in antineutrophil cytoplasmic antibody-associated vasculitis.

Harper L. Harper L. Curr Opin Rheumatol. 2010 Jan;22(1):37-42. doi: 10.1097/BOR.0b013e328331cfeb. Curr Opin Rheumatol. 2010. PMID: 19770660 Review.

5

Revascularization versus medical therapy for renal-artery stenosis.

ASTRAL Investigators; Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, Carr S, Chalmers N, Eadington D, Hamilton G, Lipkin G, Nicholson A, Scoble J. ASTRAL Investigators, et al. N Engl J Med. 2009 Nov 12;361(20):1953-62. doi: 10.1056/NEJMoa0905368. N Engl J Med. 2009. PMID: 19907042 Free article. Clinical Trial.

6

Complications of long-term therapy for ANCA-associated systemic vasculitis.

Wall N, Harper L. Wall N, et al. Among authors: harper l. Nat Rev Nephrol. 2012 Sep;8(9):523-32. doi: 10.1038/nrneph.2012.107. Epub 2012 Jun 5. Nat Rev Nephrol. 2012. PMID: 22664736 Review.

7

The complications of vasculitis and its treatment.

King C, Harper L, Little M. King C, et al. Among authors: harper l. Best Pract Res Clin Rheumatol. 2018 Feb;32(1):125-136. doi: 10.1016/j.berh.2018.07.009. Epub 2018 Aug 28. Best Pract Res Clin Rheumatol. 2018. PMID: 30526892 Review.

8

Comparison of outcomes using the rituximab originator MabThera with the biosimilar Truxima in patients with ANCA-associated vasculitis.

Antonelou M, Abro A, Heath R, Iacovou A, Ashley C, Caplan J, Morgan MD, Logan S, Harper L, Salama AD. Antonelou M, et al. Among authors: harper l. Scand J Rheumatol. 2022 Mar;51(2):135-141. doi: 10.1080/03009742.2021.1926318. Epub 2021 Sep 2. Scand J Rheumatol. 2022. PMID: 34474634

9

Predicting relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis: a Systematic review and meta-analysis.

King C, Druce KL, Nightingale P, Kay E, Basu N, Salama AD, Harper L. King C, et al. Among authors: harper l. Rheumatol Adv Pract. 2021 Mar 9;5(3):rkab018. doi: 10.1093/rap/rkab018. eCollection 2021. Rheumatol Adv Pract. 2021. PMID: 34476335 Free PMC article.

10

Cytomegalovirus infection is a risk factor for venous thromboembolism in ANCA-associated vasculitis.

King C, Patel R, Mendoza C, Walker JK, Wu EY, Moss P, Morgan MD, O'Dell Bunch D, Harper L, Chanouzas D. King C, et al. Among authors: harper l. Arthritis Res Ther. 2022 Aug 10;24(1):192. doi: 10.1186/s13075-022-02879-7. Arthritis Res Ther. 2022. PMID: 35948984 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

936 results

Search Page